FindTrial
Sign In

Dose-response relationship of TCI remifentanil inhibiting responses to endotracheal intubation in severely preeclamptic patients undergoing caesarean section

Dose-response relationship of TCI remifentanil inhibiting responses to endotracheal intubation in severely preeclamptic patients undergoing caesarean section

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022174
Enrollment
Unknown
Registered
2019-03-28
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endotracheal intubation in severely preeclamptic patients undergoing caesarean

Interventions

Group R1:TCI remifentanil 1.5ng/ml
Group R2:TCI remifentanil 2.5ng/ml
Group R3:TCI remifentanil 3.5ng/ml
Group R4:TCI remifentanil 4.5ng/ml
Group R5:TCI remifentanil 5.5ng/ml

Sponsors

Jiaxing Maternity and Child Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: One hundred severely preeclamptic patients, aged 22-36 years, weighing 62-92 kg, with body mass index =35 kg/m2, at 32-36 weeks of gestation, of ASA physical status ? or ?, undergoing caesarean section under general anesthesia.

Exclusion criteria

Exclusion criteria: Has other serious cardiovascular, respiratory diseases, diabetes mellitus, congenital abnormality observed in the fetus.

Design outcomes

Primary

MeasureTime frame
Blood Pressure;Apgar score;hemodynamics;—

Countries

China

Contacts

Public ContactXiao Fei

Department of Anesthesiology, Jiaxing Maternity and Child Care Hospital

13706597501@163.com+86 13706597501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026